Comparison Between Atorvastatin and Rosuvastatin on Secondary Percutaneous Coronary Intervention Rate and the Risk Factors in Patients with Coronary Heart Disease

(E-pub Ahead of Print)

Author(s): Jie Zhang*, Jiaqi Wang, Han Yu, Guanghua Wang, Junfang Zhang, Rui Zhu, Xuebo Liu, Jue Li.

Journal Name: Current Drug Metabolism

Become EABM
Become Reviewer


Background Statins are effective for patients in decreased low-density lipoprotein therapy. Objective We wanted to compare atorvastatin versus rosuvastatin on secondary percutaneous coronary intervention (PCI) rate and explore risk factors in coronary heart disease (CHD) patients.

Methods A cohort study with 283 CHD subjects was launched from 2011 to 2015. Cox proportional hazards regression model, Receiver Operating Characteristic (ROC) and nomogram were used to compare effect of atorvastatin and rosuvastatin on secondary PCI rate and disease risk factors. Even, we explored that why the two statins had different effects based on gene expression profile analysis.

Results Gene FFA (Freely fatty acid), AST (Aspartate Transaminase) and ALT (Alanine transaminase) showed the statistical difference between the four statin groups (P<0.05). In AA group (Continuous Atorvastatin usage), albumin was a risk factor (Hazard Ratio (HR):1.076, 95%CI (1.001, 1.162), p<0.05). In AR group (Start with Atorvastatin usage, then change to Rosuvastatin usage), ApoA was a protective factor (HR:0.004, 95%CI (0.001, 0.665), p<0.05). GLB (Galactosidase Beta) was a risk factor (HR:1.262, 95%CI (1.010, 1.576), p<0.05). In RR group (Continuous Rosuvastatin usage), ApoE was a protective factor (HR:0.943, 95%CI (0.890, 1.000), p<0.05). ALT was a risk factor (HR:1.030, 95%CI (1.000, 1.060), p<0.05).

Conclusion Patients in RA group the lowest secondary PCI rate. ALT was a risk factor in RR group. Gene Gpt (Glutamic Pyruvic Transaminase) encoded for one subtype of ALT was significantly different expression in different statin groups

Keywords: Percutaneous coronary intervention, coronary heart disease, rosuvastatin, atorvastatin, Gpt, ALTPercutaneous coronary intervention, ALT

Rights & PermissionsPrintExport Cite as

Article Details

(E-pub Ahead of Print)
DOI: 10.2174/1389200221666200310110410
Price: $95

Article Metrics

PDF: 1